Why Hematology Practices Consider Outsourcing
Hematology billing is among the most complex in medicine. It requires expertise in three distinct billing domains: chemotherapy administration coding (a hierarchical system that differs from standard procedure coding), drug buy-and-bill (J-code selection, unit calculation, drug inventory management), and specialty authorization (prior auth for high-cost drugs with payer-specific formulary rules). Finding billing staff who can handle all three domains is difficult and expensive. A coding error on a single chemotherapy claim can cost $5,000 to $50,000, making the stakes of billing accuracy exceptionally high. Outsourcing to a vendor with oncology/hematology billing expertise provides access to specialized knowledge that most small practices cannot build internally.
Cost Comparison: In-House vs. Outsourced
In-house billing for a 2 to 3 physician hematology practice requires 2 to 4 billing staff: one oncology-certified coder, one drug billing specialist (J-codes, unit calculations, drug authorization), one claims/AR specialist, and potentially a financial counselor for copay assistance enrollment. Total annual cost: $200,000 to $350,000 including salary, benefits, software, and clearinghouse fees. Outsourced billing for hematology/oncology typically charges 5% to 8% of collected revenue. A hematology practice collecting $3 million to $6 million annually (including drug revenue) pays $150,000 to $480,000 for outsourced billing. The percentage model means the vendor cost scales with drug revenue, which can make outsourcing expensive for practices with high drug volume.
Vendor Evaluation for Hematology Billing
Evaluate vendors on five hematology-specific competencies. First, chemotherapy administration coding: the vendor must demonstrate mastery of the administration hierarchy (96413, 96415, 96417, 96409, 96411, 96365, 96367, 96360). Test with 10 to 15 sample infusion timelines and compare their code assignments. Second, J-code accuracy: the vendor must correctly identify J-codes for hematology drugs (including biosimilars) and calculate billing units from doses. Third, drug authorization management: the vendor must track authorizations by drug, dose, and cycle count. Fourth, drug margin awareness: the vendor should understand buy-and-bill economics and flag negative-margin drugs. Fifth, copay assistance coordination: the vendor should track patient copay assistance enrollment and apply payments correctly.
Drug Revenue and Fee Structure
The fee structure for outsourced hematology billing requires careful negotiation because of the drug revenue component. A flat percentage of total collections (5% to 8%) applied to drug revenue can be expensive: 6% of $3 million in drug collections equals $180,000 for the drug billing alone. Some practices negotiate a tiered structure: a higher percentage on E/M and administration revenue (7% to 9%) and a lower percentage on drug revenue (3% to 4%). Others negotiate a flat per-claim or per-patient fee for drug billing. Clarify how drug wastage (JW modifier) revenue is treated in the fee calculation. The vendor should be incentivized to maximize drug margin, not just total collections.
Transition Planning
Transitioning hematology billing requires a 90-day overlap due to the complexity of drug billing. Transfer five data sets to the new vendor: patient demographics and insurance, active treatment protocols with authorized drugs and remaining cycles, drug inventory and acquisition cost records, pending authorizations and authorization expiration dates, and open AR including high-dollar drug claims. The critical risk during transition is drug authorization continuity: if the new vendor does not have the current authorization details, drug claims will be denied. Create a patient-by-patient transition document listing every active treatment patient, their current regimen, authorization number, authorized cycles remaining, and next treatment date.
Performance Metrics
Set hematology-specific performance standards. Drug claim submission: within 48 hours of treatment. Clean claim rate: 96% or higher. Drug denial rate: below 5% (lower threshold than overall because drug denials are high-dollar). E/M and administration denial rate: below 7%. AR days: 30 or less for drug claims, 28 or less for E/M. Net collection rate: 97% for drugs, 95% for E/M and administration. Administration code capture rate: 3.5+ codes per multi-drug chemotherapy session. Monthly reporting should include: drug margin by product, administration revenue per session, denial analysis by CARC code, drug inventory reconciliation, and copay assistance enrollment status.